KZIA - Spark Newswire

4 minute read

Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

Today, 10:14 PM

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.

ACER

1 minute read

Kazia Therapeutics Seeks Trading Halt Pending Announcement On Anticipated Financing Transaction

By Michael Horton

Today, 10:14 PM

-Reuters

KZIA

8 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:14 PM

On Thursday, 116 companies set new 52-week lows.

AHPI

2 minute read

Reported Late Monday, Kazia Therapeutics Announces Research Collaboration With QIMR Berghofer Medical Research Institute To Investigate The Utility Of Its Lead Asset, Paxalisib In Solid Tumors

By Benzinga Newsdesk

Today, 10:14 PM

Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR

KZIA

14 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:14 PM

On Thursday, 241 companies hit new 52-week lows.

ACHL

2 minute read

News

Kazia Launches Preclinical Collaboration With Qimr Berghofer Medical Research Institute and Announces Patent Filing

By Charles Gross

Today, 10:14 PM

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to explore novel uses of paxalisib in solid tumours.

KZIA